Analgesic effects of cyclooxygenase 2 inhibitors;Effet antalgique des inhibiteurs de la cyclo-oxygénase 2

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS., 2004, Pages

  Jayr, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Analgesia; Cox2 inhibitors; Coxibs; NSAID; Pain

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; CELECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

ANALGESIC ACTIVITY; CANCER PAIN; CHRONIC PAIN; DRUG EFFICACY; HUMAN; PAIN; POSTOPERATIVE PAIN; REVIEW; SIDE EFFECT; COMPLICATION; FEMALE; NEOPLASM;

ACUTE DISEASE; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; NEOPLASMS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULFONES; FEMALE;

EID: 2642518041     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971 ; 231 : 232-5.
2. Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 1988 ; 263 : 3022-8.
3. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 1989 ; 86 ; 1657-61.
4. Raz A, Wyche A, Fu J, Seibert K, Needleman P. Regulation of prostanoids synthesis in human fibroblasts and human blood monocyces by intetleukin-1, endotoxin, and glucocorticoids. Adv Prostaglandin Thromboxane Leukot Res 1990 ; 20 : 22-7.
5. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001 ; 410 : 471-5.
6. Hinz B, Brune K. Cyclooxygenase-2: 10 years later. J Pharmacol Exp Ther 2002 ; 300 : 367-75.
7. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996 ; 384 : 644-8.
8. Yaksh TL, Dirig DM, Malmberg AB. Mechanism of action of nonsteroidal anti-inflammatory drugs. Cancer Invest 1998 ; 16 : 509-27.
9. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998 ; 280 : 1268-70.
10. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 ; 345 : 433-42.
11. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 ; 296 : 558-66.
12. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J 1998 ; 12 : 1063-73.
13. Woolf CJ. A new strategy fot the treatment of inflammatory pain: prevention or elimination of central sensitization. Drugs 1994 ; 47 (suppl. 5) : 1-9.
14. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000 ; 355 : 646-8.
15. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998 ; 115 : 101-9.
16. Beiche F, Scheuetet S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996 ; 390 : 165-9.
17. Baba H, Kohno T, Moore KA, Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001 ; 21 : 1750-6.
18. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood-brain barrier. Nature 2001 ; 410 : 430-1.
19. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Vigor Study Group. N Engl J Med 2000 ; 343 : 1520-8.
20. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 ; 284 : 1247-55.
21. American Geriatrics Society. The management of chronic pain in older persons: AGS panel on chronic pain in older persons. J Am Geriatr Soc 1998 ; 46 : 635-51.
22. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 ; 120 : 594-606.
23. Berenbaum F. Non-steroidal anti-inflammatory agents. Rev Prat 2003 ; 53 : 502-6.
24. Crofford LJ. Clinical experience with specific COX-2 inhibitors in arthritis. Curr Pharm Des 2000 ; 6 : 1725-36.
25. Dougados M, Behier JM, Jolchine I, Calin A, van der HD, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinfiammatory drug. Arthritis Rheum 2001 ; 44 : 180-5.
26. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 ; 345 : 1809-17.
27. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994 ; 330 : 592-6.
28. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996 ; 335 : 1124-32.
29. Katz N. Coxibs: evolving role in pain management. Semin Arthritis Rheum 2002 ; 32 : 15-24.
30. Mackowiak PA. Antipyretic therapy's future. Clin Infect Dis 2000 ; 31 (suppl. 5) : S242-3.
31. Mackowiak PA. Brief history of antipyretic therapy. Clin Infect Dis 2000 ; 31 (suppl. 5) : S154-6.
32. Camu F, Beecher T, Recker DP, Verburg KM. Valdecoxib, a COX-2-specific inhibitor; is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002 ; 9 : 43-51.
33. McCrory CR, Lindahl SG. Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg 2002 ; 95 : 169-76.
34. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999 ; 94 : 504-8.
35. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999 ; 21 : 943-53.
36. Barton SF, Langeland FF, Snabes MC, LeComte D, Kuss ME, Dhadda SS et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002 ; 97 : 306-14.
37. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth 2003 ; 90 : 166-72.
38. Malan TP, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a patenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003 ; 98 : 950-6.
39. Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth 2003 ; 90 : 746-9.
40. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003 ; 125 : 1481-92.
41. Girod V, Bouvier M, Grelot L. Characterization of lipopolysaccharide- induced emesis in conscious piglets: effects of cervical vagotomy, cyclooxygenase inhibitors and a 5-HT(3) receptor antagonist. Neuropharmacology 2000 ; 39 : 2329-35.
42. Dimar JR, Ante WA, Zhang YP, Glassman SD. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996 ; 21 : 1870-6.
43. Martin GJ Jr, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine 1999 ; 24 : 2188-93.
44. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000 ; 82 : 655-8.
45. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998 ; 23 : 834-8.